Palisade Bio (PALI) announced that the Crohn’s & Colitis Foundation, through its IBD Ventures program, has approved a strategic equity investment of up to $500,000 in Palisade. The investment will support the continued clinical and mechanistic development of PALI-2108, the Company’s lead gut-microbiota-activated PDE4 inhibitor, being advanced for fibrostenotic Crohn’s disease and moderate to severe ulcerative colitis.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: